Evasion of apoptosis contributes importantly to c-Myc-induced tumorigenesis. The BH3-only Bcl-2 family members Puma and Noxa are critical pro-apoptotic transcriptional targets of p53, a major mediator of Myc-induced apoptosis and suppressor of Myc-induced tumorigenesis. Hence, we have explored the impact of their individual or combined loss on myc-driven lymphomagenesis. Notably, Puma deficiency both increased B-lineage cells and accelerated the development of B lymphoma, accompanied by leukaemia, but not of pre-B lymphoma. Noxa deficiency alone also increased B-lineage cells but did not accelerate lymphomagenesis. However, its deficiency combined with loss of one puma allele produced more rapid onset of both pre-B and B lymphomas than did loss of a single puma allele alone. Nevertheless, the acceleration evoked by loss of both genes was not as marked as that caused by p53 heterozygosity. These results show that Puma imposes a significant, and Noxa a minor barrier to c-Myc-driven lymphomagenesis. They also indicate that additional BH3-only proteins probably also drive Myc-induced apoptosis and that non-apoptotic functions of p53 may contribute substantially to its tumour suppressor role.
The ability of p53 to induce apoptosis in cells subjected to genotoxic stress or deregulated activation of oncogenes, (e.g., c-myc), is a vital component of its tumour suppressor function.
1,2 p53 triggers apoptosis through the 'Bcl-2-regulated' pathway, as the response can be inhibited by overexpression of Bcl-2 or its pro-survival homologues. [3] [4] [5] The Bcl-2 protein family, which regulates developmentally programmed cell death and cytotoxic stress-induced apoptosis, [6] [7] [8] contains three structurally and functionally distinct subgroups: Bcl-2-like pro-survival proteins, which share up to four Bcl-2 homology (BH) regions; pro-apoptotic Bax/Bak-like proteins, which contain the BH1, BH2 and BH3 regions; and the pro-apoptotic BH3-only proteins, which share only the BH3 domain. The BH3-only proteins initiate apoptosis signalling, whereas Bax/Bak-like proteins act downstream by disrupting the mitochondrial outer membrane.
Experiments with genetically modified mice have shown that just as pro-survival Bcl-2 family members can be oncogenic, 9 certain pro-apoptotic BH3-only proteins (e.g., Bim, Puma) can function as tumour suppressors. 10, 11 Moreover, links between deficiencies in BH3-only proteins -in particular Bim -and human cancer are accumulating. [12] [13] [14] Two BH3-only genes, noxa and puma, are direct transcriptional targets of p53, [15] [16] [17] although they can also be induced by p53-independent mechanisms. 15, 18 Studies with genetargeted mice have shown that Puma plays a major role in p53-mediated apoptosis of many cell types, including B and T lymphocytes, as well as in some p53-independent apoptotic pathways [19] [20] [21] and that Noxa participates in the DNA damage response of fibroblasts and keratinocytes. 19, 22, 23 Recently, we showed that the combined absence of Noxa and Puma protected mouse embryo fibroblasts from etoposide-induced apoptosis to a greater extent than loss of either gene alone; remarkably, following whole body g-irradiation, their concomitant loss protected thymocytes as potently as p53 loss. 24 As the pro-apoptotic activity of p53 is considered to be critical for its tumour suppressor function 1, 2 and Puma and Noxa appear to be the critical pro-apoptotic effectors induced by p53, animals lacking Noxa or Puma might be expected to be abnormally tumour prone. Surprisingly, however, mice lacking either of these apoptotic triggers, or even both, are not tumour prone. 19, 20, 24 Nevertheless, their loss might contribute to tumorigenesis in the context of an oncogenic lesion that activates the p53 pathway.
In Em-myc transgenic mice, a model of B-lymphoma development, 25 the high c-Myc expression throughout B-cell development provokes an expansion of cycling pre-B cells due to increased proliferation and reduced differentiation from the pre-B to the mature B-cell stage, 26 which is to a certain extent counter-balanced by increased apoptosis. 27 Although Em-myc mice all eventually develop disseminated pre-B and/or B-cell lymphomas, usually with associated leukaemia, somatic mutations to activate additional oncogenes or inactivate tumour suppressors are required. 25, 28 Transformation by Myc is greatly limited by its tendency to induce apoptosis under stress conditions, such as limiting growth factors. 27, 29, 30 Myc triggers apoptosis, in part, by activating the tumour suppressor p19Arf, which upregulates p53 by suppressing Mdm2 activity. 31, 32 Accordingly, Em-myc lymphomas often contain mutations in the p19Arf/Mdm2/p53 pathway. 33 To assess the tumour suppressor potential of Puma and Noxa, we have evaluated the impact of their individual or combined loss on lymphoma development in Em-myc mice.
Results
Myc upregulates expression of Puma and Noxa. Myc indirectly upregulates p53, 31 which would be expected to stimulate the transcription of puma and noxa. To investigate the impact of constitutive c-Myc expression on puma and noxa expression in B-lineage cells, we compared the levels of their mRNAs, and those of several other Bcl-2 family members, by qRT-PCR in pro-B, pre-B and sIg þ B cells sorted from the bone marrow of healthy (pre-malignant) Em-myc and non-transgenic mice ( Figure 1a) . As expected, all three B-cell subsets from Em-myc mice had c-myc levels at least 20-fold above those from non-transgenic littermates. The levels of noxa mRNA were B3-fold higher in pro-B cells from Em-myc than non-transgenic mice and B2.5-fold higher in the sIg þ B-cell subset but only marginally higher in the pre-B cells. Similarly, the constitutive Myc expression increased puma mRNA levels B2.5-fold in pro-B and B7-fold in sIg þ B cells but had no impact in pre-B cells. In accord with a previous study, 10 bim was also elevated in the Em-myc pro-B and sIg þ B cells, whereas bad levels rose only in the pro-B cells. In accordance with other studies, 10, 34, 35 Myc overexpression also elicited stage-specific alterations in the levels of the mRNAs for pro-survival Bcl-2 family members ( Figure 1a ): it did not change the levels of a1 and bcl-2 in pre-B cells, but decreased both in sIg þ B cells, whereas bcl-x levels were decreased in Em-myc pro-B and pre-B cells but not in sIg þ B cells. Figure 1 Puma and Noxa expression is increased in B cells from Em-myc mice. (a) Differences in the levels of RNA for Bcl-2 family members and Myc between cells from Em-myc and non-transgenic mice. Pro-B, pre-B and B-cell subsets were FACS purified from healthy 5-to 6-week-old Em-myc or non-transgenic syngeneic (C57BL/6) mice. SYBR green real-time PCR analysis was performed on cDNA. Relative RNA expression levels were calculated by normalising to the signal for b-actin in each sample and then dividing the transgenic by the non-transgenic value. Mean expression is shown ± S.E.M. of cells from 3-4 individual mice of each genotype from at least three separate experiments. (b) Western blot analysis of Puma and b-actin (loading control) on protein isolated from the cell populations described in A. Puma-deficient thymocytes were included as a control for antibody specificity. Protein size standards in kDa are indicated on the left Western blot analysis confirmed the higher Puma expression in the Em-myc pro-B and sIg þ B cells ( Figure 1b ) and also indicated that Puma protein levels are higher in Em-myc pre-B cells. The increase in Puma protein in the pre-B cells might result from translation of the increased mRNA in the pro-B cells. Unfortunately, we have not identified a suitable antibody for mouse Noxa.
Loss of Puma expanded the B-cell compartment of El-myc mice. No abnormalities in haematopoiesis have been observed in unstressed puma À/À mice, 19, 20 but the B-lineage compartment of pre-malignant Em-myc mice is perturbed by increased cell cycling, 26 which is partially balanced by increased apoptosis. 27 To determine how the absence of Puma affects haematopoiesis in that context, we enumerated leukocytes in the peripheral blood of young tumour-free animals. Em-myc/puma À/À mice had B4-fold more leukocytes than wt non-transgenic littermates and B3-fold more than Em-myc littermates (Figure 2a ). This increase was specific to the transgenic mice, as non-transgenic puma À/À , puma þ /À and wt mice all had similar numbers. At 5-6 weeks of age, blood leukocyte levels of Em-myc mice and Em-myc/puma þ /À littermates remained higher than in their non-transgenic counterparts, but the Em-myc/puma À/À mice had the highest level (Figure 2b ). Analysis for B-lymphoid differentiation markers revealed that the leukocyte excess in Puma-deficient Em-myc animals reflected an increase in B-lineage cells, as their blood contained several-fold more pro-B/pre-B cells (B220 þ sIg À ), virgin B cells (B220 þ sIgM þ IgD lo ) and mature B cells (B220 þ sIgM þ sIgD hi ) compared with Em-myc wt mice (Figure 2b) . A comparable increase was observed for virgin B cells in the lymph nodes and spleen (Supplementary Figure 1) . Accordingly, the pre-malignant Em-myc/puma À/À mice had marked splenomegaly compared with Em-myc mice (Po0.02) (Figure 2c ), and this must reflect the excess total B-lineage cells, because, as expected, loss of Puma on the Em-myc background did not affect the numbers of CD4 þ or CD8 þ T cells, macrophages, granulocytes or nucleated erythroid progenitors in any tissue examined (data not shown).
We also examined the bone marrow, where B cells develop in adult mice. As reported, 26 wt Em-myc bone marrow had around two times as many pro-B and pre-B cells as nontransgenic littermates but fewer sIg þ B cells (Figure 2d ). Only the sIg þ B cells (but not the pro-B and pre-B cells) of Em-myc/ puma À/À mice were significantly elevated above the levels in wt Em-myc mice (Figure 2d Blood cellularity and subset composition in pre-neoplastic 5-to 6-week-old mice of the indicated genotypes. All differences between non-transgenic and Em-myc mice were significant for all puma genotypes (Po0.05) except for mature B cells from non-transgenic versus Em-myc/puma À/À mice. For comparisons of Em-myc transgenic mice of the different puma genotypes, statistically significant differences in addition to those indicated, included all subset comparisons between Em-myc/puma þ /À and Em-myc/puma À/À mice. (c) Spleen weights (means ± S.E.M.) of pre-neoplastic 5-to 6-week-old mice. Differences between non-transgenic and Em-myc mice were significant for all puma genotypes (Po0.03), and for those indicated. (d) Bone marrow cellularity (both femora) and subset composition in pre-neoplastic 5-to 6-week-old mice of the indicated genotypes. Differences between non-transgenic and Em-myc mice were significant (Po0.05) for all puma genotypes for total B and pre-B cell comparisons and for reduction in mature B cells for wt versus Em-myc and wt versus Em-myc/puma À/À mice. For comparisons of the Em-myc transgenic mice of the different puma genotypes, all statistically significant differences are indicated. Values represent means ± S.E.M. from 4 to 8 mice of each genotype. *Po0.05, **Po0.01, ***Po0.005
in Em-myc/puma À/À over wt Em-myc animals ( Figure 2 ) indicated that Puma loss might retard the apoptosis normally induced by c-Myc overexpression. 29, 30 To investigate this, pro-B, pre-B and virgin/mature B cells from young healthy mice were cultured in simple medium (representing cytokine deprivation) or with the DNAdamaging drug etoposide. Em-myc/puma þ /À and Em-myc/ puma À/À pro-B cells (Supplementary Figure 2a) and sIg þ B cells (Supplementary Figure 2b) were no more refractory to either stimulus than their Em-myc wt counterparts. However, the absence of Puma significantly protected pre-B cells against cytokine deprivation and DNA damage (Figure 3) , and the survival of Em-myc/puma þ /À pre-B cells was intermediate for cytokine deprivation. The virgin/mature B cells were also tested for their response to cross-linking of the B-cell antigen receptor, but the Em-myc/puma À/À and wt Em-myc B cells died at the same rate (data not shown).
Loss of Puma accelerated B-cell lymphomagenesis in El-myc mice. The effect of Puma on cellularity of the B lineage in Em-myc mice and on transgenic pre-B-cell survival led us to examine how Puma loss affected lymphomagenesis by monitoring cohorts of Em-myc mice of different puma genotypes. Em-myc (puma þ / þ ) mice (n ¼ 64) became ill between 50 and 470 days of age (median 100 days) as reported earlier, 25, 28 and the Em-myc/puma þ /À mice (n ¼ 100) succumbed no faster (median 95 days, P ¼ 0.46; Figure 4a ). In contrast, the Em-myc/puma À/À mice (n ¼ 33) had a median survival of 66 days, and all were unwell by 110 days of age, when a quarter of the wt Em-myc animals remained healthy (Po0.0001) (Figure 4a ). Despite this acceleration, the lymphoma development in Em-myc/ puma À/À mice remained slower than in Em-myc/p53
þ /À animals (n ¼ 23, Po0.0001) (Figure 4a ).
Sick Em-myc/puma À/À mice presented with enlarged lymph nodes, spleen, and thymus, as in classical Em-myc lymphoma. 25, 28 To confirm that the lymphomas were malignant, tumour cells (2 Â 10 6 ) were injected intra-peritoneally into C57BL/6 recipients. Five of seven control Em-myc, six of seven Em-myc/puma þ /À and seven of eight Em-myc/puma À/À lymphomas produced tumours in recipients within 11-54 days, comparable to the 90% transplantability reported earlier for Em-myc lymphomas. 25, 28 Immunophenotyping of the primary lymphomas revealed, as expected 28 that nearly all comprised B220 þ sIg À pro-B/ pre-B lymphomas or B220 þ sIgM þ sIgD lo B-cell lymphomas ( Supplementary Figures 3a and b) , although a small minority contained both sIg À and sIg þ B populations (Supplementary Figure 3c) . The puma genotype did not significantly affect the overall proportion of pre-B versus mature B-cell tumours. Pre-B lymphomas comprised 17/26, 27/53, and 7/17 of the tumours arising in wt, puma þ /À and puma À/À mice, respectively ( Figure 4d ). Nevertheless, the accelerated morbidity of the Em-myc/puma À/À cohort was due to earlier onset of sIg þ B lymphomas, which arose much sooner than in Em-myc/ puma þ /À or Em-myc mice ( Figure 4b ): median survival was 91 days for Em-myc/puma À/À versus 174 days for Em-myc/ puma þ /À mice (Po0.001). Although Em-myc/puma þ /À mice also developed sIg þ B lymphomas slightly earlier than Emmyc mice (whose median survival was 244 days), their overall survival was not significantly impaired. The accelerated disease in the absence of Puma was entirely ascribable to the faster onset of B lymphomas as pre-B lymphomas did not arise earlier in Em-myc/puma À/À mice than control Em-myc animals ( Figure 4c ). the absence of Puma, or even loss of one allele, resulted in a higher leukaemic burden than in wt Em-myc mice. Although blood leukocyte counts at autopsy varied markedly amongst Em-myc/puma þ /À and Em-myc/ puma À/À mice, the mean count was 43-fold higher for Em-myc/puma À/À than wt Em-myc mice (Po0.005) (Figure 4e ). Splenomegaly correlated with the extent of leukaemia, spleen weights being 1.6-fold greater in ill Em-myc/puma À/À than ill wt Em-myc animals. As reported for Em-myc/bim À/À mice, 10 the increased leukaemia in Em-myc/puma À/À mice occurred exclusively in the setting of sIg þ B-cell lymphomas: their mean leukocyte numbers were four times that seen in animals succumbing to pre-B cell tumours (209 ± 125 Â 10 6 /ml versus 51 ± 32 Â 10 6 /ml; Po0.01). Leukaemia was also several-fold higher in Em-myc/puma þ /À mice succumbing to sIg þ B-cell lymphomas compared with those succumbing to pre-B lymphomas (data not shown).
Loss of both Puma and Noxa did not enhance the pre-malignant phenotype more than loss of Puma alone. We have previously shown that functional overlap of Noxa and Puma exists in DNA damage-induced apoptosis of certain cell types, including pro-B/pre-B cells. 24 We therefore examined whether loss of Noxa, like loss of Puma, had an impact on the Em-myc mouse model. To do this, we first investigated whether loss of Noxa, alone or together with loss of one or both puma alleles, affected the haematopoietic system of healthy young Em-myc mice. On the Em-myc background, Noxa deficiency alone did not elevate blood leukocytes Figures 1a and 4c) although, perhaps surprisingly, the levels of pre-B and sIg þ cells were lower than those in Em-myc/noxa À/À animals ( Figure 5c ). In the bone marrow, Em-myc mice deficient for both Noxa and Puma also had fewer immature B cells than in the Em-myc/noxa À/À mice and strikingly fewer pro-B cells than either the Em-myc/noxa À/À or Em-myc/puma À/À mice (Po0.0001) (compare Figure 2d with Figure 5a ). The reason for this reduction is not clear. Figure 4c) .
The elevated levels of noxa mRNA in Em-myc B-lymphoid cells (Figure 1a ) and the increased cell numbers within bone marrow B-cell subsets provoked by Noxa loss suggested that loss of Noxa, like that of Puma, might retard the apoptosis normally induced by c-Myc. Survival assays with FACSpurified sub-populations, however, showed that the absence of Noxa alone did not protect cells at any stage of B-cell development against either cytokine deprivation or etoposide, compared with cells from Em-myc or Em-myc/puma þ /À mice (Supplementary Figure 5) . This is in contrast to loss of Puma, where protection relative to Em-myc was significant (Figure 3) . B-lymphoid cells from Em-myc/noxa À/À puma À/À mice did not survive better in culture than those from Em-myc/puma À/À mice.
Combined loss of Noxa and Puma in El-myc mice accelerated pre-B as well as B-lymphomagenesis. The overlapping roles of Noxa and Puma in DNA damageinduced apoptosis of pro-B/pre-B cells 24 indicated to us that Noxa and Puma might cooperate to limit Myc-induced lymphomagenesis. We first investigated whether loss of Noxa alone could promote lymphomagenesis, by monitoring cohorts of Em-myc/noxa þ /À and Em-myc/noxa À/À mice. Loss of Noxa alone had little effect. The median survival of Em-myc/noxa þ /À (n ¼ 76), Em-myc/noxa À/À (n ¼ 56) and Em-myc (n ¼ 64) animals was very similar (Supplementary Figure 6) . Indeed, tumour development in the absence of Noxa actually delayed onset of pre-B lymphomas (Po0.05, Figure 6c ), for unknown reasons.
Next, cohorts of Noxa-deficient Em-myc transgenic mice lacking one or both alleles of puma were monitored, to investigate if a role for Noxa in tumour suppression might become evident when combined with Puma deficiency. Strikingly, Em-myc/noxa
mice (n ¼ 29) succumbed to lymphoma with a median survival of 77 days (Figure 6a ), a rate significantly faster (Po0.0001) than that seen in Em-myc/puma þ /À mice (median survival 95 days, Figure 4a ). Indeed, the rate approached that observed with Em-myc/puma À/À mice (Figure 4a ). In contrast, the loss of one allele each of noxa and puma did not appreciably alter survival compared to loss of one puma allele alone (median survival 91 days, n ¼ 13, data not shown). Loss of both the puma and the noxa alleles (Em-myc/noxa À/À puma À/À mice) further accelerated tumour onset (median survival 65 days, n ¼ 11) over that in Em-myc/noxa À/À puma þ /À mice (Po0.04), albeit not significantly faster than in Em-myc/puma À/À mice (P ¼ 0.12). The accelerated tumorigenesis in Em-myc/noxa
and Em-myc/noxa À/À puma À/À mice involved both the pre-B and B-cell compartments ( Figures 6B and C) . Thus, Noxa has a role in restraining Myc-induced lymphomagenesis, albeit less substantial than that of Puma.
Although Noxa loss alone did not affect development of B-cell lymphomas, on a puma heterozygous background Noxa loss significantly accelerated B-cell lymphoma onset (median survival 86 days) compared with puma heterozygosity alone (median survival 174 days; Po0.01) (Figure 6b) . Curiously, although Noxa loss alone actually delayed pre-B lymphoma development (Po0.05), additional loss of one puma allele accelerated pre-B lymphoma onset (Figure 6c) , the Em-myc/noxa À/À puma þ /À mice succumbing earlier than Em-myc/puma þ /À mice (median survival 93 versus 140 days; Po0.02). Notably, Em-myc/noxa À/À puma À/À mice also succumbed to pre-B lymphomas significantly earlier than Em-myc/puma À/À mice (median survival 71 versus 107 days; Po0.02) (compare Figure 6c with Figure 4c ). The proportion of pre-B versus sIg þ B-cell tumours arising in Em-myc/puma þ /À and Em-myc/puma À/À was not, however, affected by additional loss of noxa (Figure 6d) .
In contrast to Puma loss, Noxa loss did not increase the leukaemic burden in Em-myc mice. The mean white blood cell counts and spleen weights at autopsy for ill Em-myc/noxa þ /À (not shown) and Em-myc/noxa À/À mice (Figure 6e and f) were not significantly greater compared with their ill Em-myc counterparts. Although killed Em-myc/noxa À/À puma þ /À mice had spleen weights and blood leukocyte numbers similar to Em-myc/puma À/À mice (compare Figures 4e and f with  Figures 6e and f) , loss of the second puma allele on the Noxa-deficient background provoked no greater increase.
Loss of heterozygosity for puma is not required for El-myc-induced lymphomagenesis. The faster tumour onset in Em-myc/noxa
mice could be due simply to the absence of noxa, but it might instead reflect loss of the remaining puma allele. To distinguish between these possibilities, we performed allelespecific PCR for puma on 12 randomly selected Em-myc/ noxa À/À puma þ /À tumours. All retained the wt puma allele (Figure 7a ). To rule out the possibility that the wt puma allele had been amplified from normal stromal tissue contaminating the lymphoma specimen, four tumours were FACS-sorted for large B220 þ lymphoma cells. The allele-specific PCR yielded the same result (Figure 7b ). Western blotting of eight Em-myc/ noxa À/À puma þ /À tumours tested revealed Puma protein (Figure 7c ), also arguing against loss of heterozygosity. Interestingly, however, the Puma levels were markedly reduced in several tumours (e.g., no. 15, 34 and 42 in Figure 7c ). This suggests that Myc-induced lymphomagenesis sometimes selects for reduced Puma expression, at transcriptional and/or post-transcriptional levels.
Loss of Puma but not loss of Noxa reduced selection for a mutated p53 pathway in El-myc lymphoma. To investigate whether lymphomas from Em-myc/puma À/À mice differed from control Em-myc lymphomas in their need to select for mutations in the p19Arf/p53 pathway, the p53 pathway status of randomly selected tumours was examined in several ways: from the levels of p19Arf protein (as p53 normally downregulates p19Arf expression by a negative feedback loop 33 ), the presence or deletion of the Ink4a/Arf locus by genomic PCR, 36 À/À lymphomas tested exhibited high p19Arf levels, 1 of 9 Em-myc/noxa À/À puma À/À lymphomas (no. 104 in Supplementary Figure 7) had a clear mutant p53 phenotype, as evidenced by high levels of both the Arf and p53 proteins. A lower level of p19Arf was found in a few tumours (e.g., no. 291, 211 and 362 in Figure 8b) ; we think the sensitivity of the antibody used allowed detection of Arf upregulation by oncogenic stress in the absence of loss of p53 function, 38 as those tumours retained wt p53 function by all other criteria.
Six lymphomas lacking Puma alone were examined in most detail. None of them expressed a high level of p53 protein (Figure 8c) , had a p53 mutation detectable by sequencing or had deleted the Ink4A/Arf locus (Supplementary Figure 8 and data not shown). In addition, none of the 11 cell lines derived from Em-myc/puma À/À lymphomas were refractory to treatment with etoposide, as was, in contrast, the known p53 mutant lymphoma, Em-myc/noxa À/À puma À/À no. 104 (Supplementary Figure 8 and data not shown) . Thus, although the absence of Puma does not totally ablate the selection for mutations in the p53 pathway, it appears to substantially reduce it.
Discussion
Although the BH3-only protein Puma and, to a lesser extent, Noxa, are crucial for apoptosis mediated by the tumour suppressor p53, mice deficient for noxa or puma, 19, 20, 22 or even both, 24 have not proven prone to tumour development. Nonetheless, we reasoned that Puma and Noxa might constrain tumour development in the context of an oncogenic lesion that promotes apoptosis. As the major barrier to Myc-induced lymphomagenesis is thought to be Myc-induced apoptosis, which acts predominantly through the p19Arf-p53 pathway, regulated by the Bcl-2 protein family, 32 we have explored whether loss of Puma and/or Noxa could substitute for p53 loss in accelerating Myc-induced lymphomagenesis.
Consistent with a role in mediating Myc-induced apoptosis, puma and noxa mRNA expression levels were elevated in pro-B and mature B cells from Em-myc mice, albeit not in pre-B cells. Two pathways for induction of apoptosis by c-Myc have been identified. In the better-studied path, c-Myc induces p19Arf expression, and p19Arf in turn prevents the degradation of p53 by sequestering its ubiquitin ligase, Mdm2. 31, 37 The resulting elevated p53 level induces transcription of noxa and puma, [15] [16] [17] which most likely explains the elevated levels of noxa and puma mRNA and of Puma protein produced by Myc. However, at least in bone marrow-derived B-lymphoid cells 35 c-Myc can also induce apoptosis by a p19Arf-and p53-independent mechanism, 39 mediated in part by induction of Bim, 10 as well as repression of anti-apoptotic Bcl-x L 34 and Bcl-2. 10 Theoretically, c-Myc might also enhance Puma and Noxa expression by this second pathway.
Loss of Puma impaired the Myc-induced apoptotic programme. Puma loss protects diverse cell types, including B lymphocytes, against a range of apoptotic stimuli both in vitro 19, 20 and in vivo. 21, 24 Pertinently, Puma loss rendered growth factor-deprived myeloid progenitor cells refractory to c-Myc-induced apoptosis in culture. 20 Consistent with this, compared with Em-myc (wt) cells, Em-myc pre-B cells deficient for Puma were partially protected from spontaneous death in vitro (cytokine deprivation) and presumably also in vivo.
In accordance with the enhanced survival of Em-myc/ puma À/À pre-B cells in vitro, pre-malignant Em-myc/puma À/À mice had more pre-B cells in their peripheral blood than did control Em-myc animals. In addition, the number of mature B cells in the bone marrow was increased, consistent with the acceleration in B-lymphoma development observed in Em-myc/puma À/À mice. Lastly, pre-B cells lacking Puma were partially protected from DNA damage-induced death. Conversely, Noxa-deficient pre-neoplastic Em-myc mice exhibited excess pre-B and B cells in the bone marrow, but these cells did not survive better in vitro with the stimuli tested and the increase in the bone marrow was not associated with acceleration in either pre-B or B-cell lymphoma. These findings suggest that the number of B-lymphoid cells present in the pre-malignant state need not correlate with the rate of tumour onset. Consistent with this idea, Em-myc mice deficient for Bcl-2 had much fewer B-lymphoid cells but developed lymphomas as rapidly as wt Em-myc mice. 40 Loss of Puma may accelerate Em-myc-induced lymphomagenesis not only by increasing the number of target cells but also by prolonging the survival of small numbers of pre-B cells subjected to limiting cytokine conditions and/or oncogenic stress, thereby increasing their chance acquisition of oncogenic lesions that cooperate with Myc in neoplastic transformation. As more Puma-deficient mice succumbed to sIg þ B lymphomas than pre-B lymphomas, Puma loss may preferentially allow inappropriate cell survival at the pre-B to sIg þ B-cell transition.
puma heterozygosity increased tumour burden but did not hasten tumour onset. Loss of one puma allele was not sufficient to accelerate tumour onset significantly, even for B lymphomas. This was somewhat surprising, given the significant protection from apoptosis afforded by haploinsufficiency of puma in lymphoid cells [19] [20] [21] and the finding that a shRNA construct, which diminished but did not abolish Puma expression, accelerated lymphomagenesis in lethally irradiated mice reconstituted with fetal liver-derived stem cells from Em-myc mice. 11 Although the level of puma knockdown achieved may have exceeded 50%, it is also possible that c-Myc-induced lymphomagenesis in irradiated, reconstituted mice is more sensitive to Puma dosage than that in unmanipulated Em-myc mice. Puma knockdown might, for example, have enhanced survival of fetal liver stem cells during the in vitro infection period with the shRNA retrovirus, thereby facilitating more rapid lymphomagenesis in the transplant recipients.
Interestingly, ill Em-myc/puma À/À mice and even some Em-myc/puma þ /À mice exhibited higher levels of leukaemia and splenomegaly than those seen in ill wt Em-myc mice. As lymphoma/leukaemia cells in wt Em-myc mice exhibit spontaneous apoptosis, 36 Puma must play a critical role in the death of these cells in vivo and thereby limit their accumulation. However, the increased leukaemia and spleen size in sick Em-myc/puma þ /À mice did not lead to significantly earlier deaths compared with Em-myc (wt) mice.
Puma delayed the onset and limited the tumour burden of B-cell lymphoma in El-myc mice. Pre-B lymphomas predominate in wt Em-myc mice, 10, 28 development of sIg þ B lymphomas, which arose much earlier in the Em-myc/puma À/À mice. Unlike Bim, 10 however, Puma proved not to be important for apoptosis at the B-cell receptor checkpoint, as loss of Bim but not of Puma protected against killing by cross-linking of the B-cell antigen receptor.
Thus, despite the marked similarities of loss of Bim and loss of Puma on Myc-induced lymphomagenesis -both yielding more rapid sIg þ B lymphomas with associated leukaemiaslightly different stages of development may be affected. The increased Puma protein levels at the pre-B stage may suggest that Puma plays a role at the pre-B to B checkpoint. At that developmental stage, the process of Ig light chain gene rearrangement, which requires DNA breakage, may both predispose the cells to acquire oncogenic mutations and render them sensitive to Puma-mediated apoptosis. The predominant mature B-cell immunophenotype of Pumadeficient tumours in this study contrasts with the report that tumours arising in mice receiving shRNA-mediated knockdown of either puma or p53 were pre-B lymphomas, but the phenotype of only three lymphomas of each genotype was reported and the pre-B compartment in that system might be more vulnerable to Puma knockdown.
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Noxa and Puma can cooperate to affect tumour onset in both pre-B and B cells. It is not surprising that Puma generally has a greater role in apoptosis than Noxa, because Puma (like Bim) can engage and inactivate all of the pro-survival Bcl-2 family members, whereas Noxa antagonises only Mcl-1 and A1. 41, 42 Nevertheless, the functional overlap of Noxa and Puma in DNA damageinduced apoptosis of certain cell types, including pro-B/pre-B cells, 24 indicated that Noxa and Puma might cooperate in suppressing Myc-induced lymphomagenesis. This did indeed occur to a significant extent, as the loss of Noxa on a puma þ /À background accelerated Em-myc-induced lymphomagenesis almost as much as loss of both puma alleles. Moreover, loss of both Puma and Noxa accelerated the development of pre-B as well as mature B-cell tumours. As loss of Puma alone did not accelerate development of pre-B lymphoma, Noxa must contribute at least in the pro-B/pre-B compartment to tumour suppression. It is possible that when Puma function is compromised, for example in pre-malignant Em-myc/puma À/À B-lineage cells, the levels and/or activation state of Noxa are heightened. Their synergy was illustrated by step-wise increases in B-cell subsets in the peripheral blood observed with loss of one or both alleles of puma on a Noxa-deficient background.
The accelerated tumour onset in Em-myc/noxa À/À puma þ /À mice was not accompanied by increased leukaemia/lymphoma burden, as spleen size and leukocyte numbers resembled those in Em-myc/puma þ /À mice. As we found no evidence that the acceleration was associated with loss of the remaining puma allele in Em-myc/noxa À/À puma þ /À mice, loss of one allele of puma and both noxa alleles may reach a threshold of apoptosis resistance sufficient for tumorigenesis. Nevertheless, the markedly low Puma protein level observed in a number of tumours with a single puma allele may well indicate that tumorigenesis can select for suppression of expression from that allele at the transcriptional and/or post-transcriptional level. 43 It is curious that although Noxa deficiency accelerated Myc-driven lymphoma development in a Puma heterozygous background, Noxa deficiency in a Puma wild-type background appeared to delay the onset of at least the pre-B tumours. At present the basis for this difference is unknown, as Noxa and Puma both function at least primarily by engaging pro-survival family members, albeit with overlapping specificity. The fact that Noxa and Puma can be regulated in multiple ways might be relevant. We do not think the differing impact of Noxa deficiency on tumorigenesis reflects some compensation between Noxa and Puma, because we have previously reported 24 that loss of Puma had no impact on the expression of Noxa or three other BH3-only proteins (Bim, Bad or Bid) and ). Western blot analysis of (b) p19Arf and b-actin (loading control), or (c) p53, and Hsp70 (loading control) in randomly selected Em-myc lymphomas of the indicated puma genotypes. p53 À/À mouse embryonic fibroblasts (MEF) or MEF immortalised with SV40 large T antigen, were included as positive controls for p19Arf overexpression and p53 overexpression, respectively. In (c) the MEF control was run on the same gel but a lane not required was spliced out of this gel. Protein size standards in kDa are indicated on the left that, conversely, loss of Noxa has no impact on the expression of Puma, Bad, Bim or Bid, in either unstressed lymphoid cells or those exposed to two apoptotic stimuli. Furthermore, we are aware of no reported evidence for compensating changes in expression of BH3-only proteins in other systems.
Loss of both Noxa and Puma was not equivalent to loss of p53 in lymphomagenesis but loss of Puma did reduce selection for p53 loss. Clearly, neither loss of Puma, nor even loss of both Noxa and Puma, accelerated Em-mycinduced lymphomagenesis as much as loss of even one allele of p53. Interestingly, shRNA-mediated knockdown of puma accelerated retroviral c-Myc-induced lymphoma development as potently as did knockdown of p53, 11 perhaps due to differences in that experimental system (see Discussion above). Pertinently, in response to stimuli that activate p53, the puma knockdown cells underwent G1 cell cycle arrest normally, 11 consistent with the notion that Puma mediates p53's apoptotic action but not its cell cycle arrest function. 11, 16, 17 Collectively, these findings indicate that the pro-apoptotic activity of p53 is only one of the ways it safeguards against tumour development. Its roles in cell cycle arrest, DNA repair and cellular senescence are likely to contribute to tumour suppression. 1 We assessed the functionality of the p53 pathway in the lymphoma cells from the levels of p19/Arf protein (as p53 normally downregulates p19/Arf expression by a negative feedback loop 33 ), the presence of the Ink4a/Arf locus by genomic PCR 36 the level of p53 protein (high levels indicating mutant, stabilised p53 protein) and by sequencing of the p53 gene. We found only a single Puma-deficient lymphoma (which also lacked Noxa) in which the p53 pathway was clearly inactive. Garrison et al. 43 have now also reported that the p53 pathway is perturbed in some Puma-deficient lymphomas , in contrast to a prior study involving knockdown of puma.
11 Hence, we conclude that the loss of Puma does not entirely supplant the need for loss of p53 function, but it does appear to substantially reduce the selective pressure. Retention of some selection for p53 loss is to be expected, because p53 can prevent tumour development through several non-apoptotic mechanisms, such as DNA repair and senescence. 1 Concluding remarks. In the Em-myc lymphoma model, Puma appears to have a major tumour suppressor function, particularly in sIg þ B cells, where Bim seems to have a similar role. 10 Although the role of Noxa seems more limited, the accelerated lymphomagenesis in both the pre-B and B-cell compartments produced by loss of Noxa on a puma heterozygous background demonstrates that it can contribute. The cell type-specific action of Noxa and Puma demonstrated here underlines the complexities of the apoptotic programme and the process of tumorigenesis and has important implications for the understanding and treatment of human cancer. As around half of all human tumours have lost p53 function, it will be important to learn how to restore this apoptotic pathway by identifying other ways to increase Puma or Noxa expression or to mimic their function, such as with BH3 mimetic agents.
Biosystems) and the QuantiTect SYBR Green PCR Kit (Qiagen) in 15 ml reaction volumes. Data analyses were performed with the DCT method using b-actin as an internal control. Primer sequences are provided in the Supplementary Materials.
Analysis of Ink4A/Arf locus and p53 mutation status in lymphomas. Vials of cryo-preserved lymphomas were thawed, dead cells removed using a Ficoll gradient and genomic DNA generated. Multiplex PCR analysis of genomic DNA for the Ink4A/Arf locus was performed to reveal gross deletions, using exon-specific primers for a-actin, exons 2, 1a and 1b as described earlier. 36, 45 Sequencing of p53 from genomic DNA was performed using two primer sets designed for each of exons 4-10 (the second set used if required for clarification). PCR products were purified and sequencing was performed using the BigDye Terminator cycle sequencing kit (Applied Biosystems). Primer sequences are available upon request.
Statistical analysis. Prism software (GraphPad Software Inc.) was used for generating Kaplan-Meier plots and for performing statistical analysis (using a log-rank test) of survival of mice and tumour onset. All other statistical analyses used two-tailed t-tests assuming equal variances. Cell counts and spleen weights were tested on the log-scale, whereas percentage data were tested on the arc sine scale. 46 Trend test was performed by linear regression. P-values of less than 0.05 were considered to indicate statistical significance.
